Proxy Materials

Annual
Report

Our report on activities & financial performance throughout the year.

View Document
Proxy
Statement

Details about our annual meeting & matters to be voted upon.

View Document
Request
Materials

Request paper copies online now, by email or by phone by dialing 866-648-8133.

Vote Now

Your vote is important!
Vote online now or by phone by dialing 844-925-2423.

VOTE NOW

Meeting Details

Note: You must register by the deadline to be eligible to participate in the meeting.

Date and Time:

October 14, 2022

8:00 a.m. Eastern Time

Registration Cutoff:

October 13, 2022
5:00 p.m. Eastern Time

REGISTER NOW
about us

About Us

TCR² is an innovative immunotherapy company developing the next generation of T cell therapies for patients suffering from cancer. Our proprietary TRuC™ (TCR Fusion Construct) T cells – a novel T cell therapy platform – reprogram the natural T cell receptor complex to recognize and kill cancer cells using the full power of T cell signaling pathways independent of HLA.

Learn More